• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Pfizer Ltd.
    31 Jul 2025, 11:24PM
    5194.50
    -1.25%
    Trump Sets Sept 29 Deadline For J&J, Pfizer, Other Pharma Firms To Lower US Drug Prices
    Trump Sets Sept 29 Deadline For J&J, Pfizer, Other Pharma Firms To Lower US Drug Prices
    NDTV Profit
    Donald Trump, in his letter to big pharma company CEOs, has demanded "most-favored-nation" pricing for Medicaid.
    Copy LinkShare onShare on Share on Share on
    Pfizer Ltd. is trading below its 30 day SMA of 5507.5
    logo
    Sun Pharmaceutical Industries Ltd.
    31 Jul 2025, 10:49PM
    Estimates Miss
    1706.70
    -1.56%
    Sun Pharma Q1 net profit falls 20% Y-o-Y; revenue rises 9%
    Business Standard
    Litigation, drug discontinuation weigh on earnings; US market remains sluggish even as India sales and Leqselvi launch boost specialty push
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical I.. has an average target of 2105.29 from 7 brokers.
    Sun Pharma has no plans to shift manufacturing to US, says management
    Business Line | 31 Jul 2025, 09:38PM 3 more
    Sun Pharma Q1 results: PAT dips 20% to 2,279 crore; revenue rises 8.6%
    Business Standard | 31 Jul 2025, 04:43PM
    Sun Pharmaceutical Q1 Results: Profit Falls 20% As Exceptional Loss Weighs
    NDTV Profit | 31 Jul 2025, 03:18PM
    Sun Pharma Q1 Results: Cons profit falls 20% YoY to Rs 2,278 crore, but revenue rises 10%
    Economic Times | 31 Jul 2025, 02:40PM
    logo
    Mankind Pharma Ltd.
    31 Jul 2025, 08:59PM
    2567.20
    -0.32%
    Mankind Pharma Q1 PAT drops 17.4% despite 24% revenue growth, costs surge
    Business Standard
    Input and finance costs weigh on profitability; chronic, consumer health and BSV acquisition support top line
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 640 to 648 in Jun 2025 qtr.
    Mankind Pharma Q1 results: Profit dips 17% to 445 cr; revenue rises
    Business Standard | 31 Jul 2025, 07:59PM 1 more
    Mankind Pharma Q1 Results: Profit Declines 18%, Revenue Up 25%
    NDTV Profit | 31 Jul 2025, 07:12PM
    logo
    Aurobindo Pharma Ltd.
    31 Jul 2025, 05:08PM
    Acquisition Results
    1139.80
    -1.57%
    Lannett deal gives Aurobindo Pharma a strategic edge amid US tariff concerns
    Business Line
    The acquisition brings cost synergies, SG&A rationalisation, and access to government procurement programs due to the local footprint.
    Copy LinkShare onShare on Share on Share on
    Aurobindo Pharma Ltd.'s price crossed below 100Day SMA today
    logo
    Orchid Pharma Ltd.
    31 Jul 2025, 01:10PM
    740.40
    5.00%
    Orchid Pharma hits 5% upper circuit in trade; why is the stock in demand?
    Business Standard
    Orchid Pharma shares were locked in a 5 per cent upper circuit at 740.1 per share on BSE; here's why
    Copy LinkShare onShare on Share on Share on
    Orchid Pharma Ltd. is trading below its 100 day SMA of 755.1
    logo
    J B Chemicals & Pharmaceuticals Ltd.
    30 Jul 2025, 08:46PM
    1769.30
    -0.75%
    JB Pharma Q1 results: Net profit up at 14% to 202 cr, revenue rises 9%
    Business Standard
    JB Chemicals & Pharmaceuticals Ltd on Wednesday reported a 14 per cent rise in net profit to Rs 202 crore in the June quarter. The company had posted a net profit of Rs 177 crore in the corresponding period of the previous fiscal year, JB Chemicals & Pharmaceuticals (JB Pharma) said in a regulatory filing. Revenue in the first quarter stood at Rs 1,094 crore as against Rs 1,004 crore in the same period a year ago, up 9 per cent, it added. "The domestic business recorded approximately 14 per cent value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio. Our major brands & their franchises are also performing well," JB Pharma CEO and Wholetime Director, Nikhil Chopra said. He further said, "The CDMO (contract development and manufacturing organisation) business momentum is likely to sustain in coming quarters." The company said its domestic formulations business recorded revenue of Rs 678 crore as against Rs 595 crore in the first...
    Copy LinkShare onShare on Share on Share on
    J B Chemicals & Phar.. has an average target of 2030.00 from 2 brokers.
    logo
    Aurobindo Pharma Ltd.
    30 Jul 2025, 08:45PM
    Acquisition Results
    1139.80
    -1.57%
    Aurobindo Pharma to acquire US-based drug-makerLannett Company for 2185 cr
    Business Line
    Lannett has been is a US based manufacturer and supplier of superior quality, complex generic pharmaceuticals
    Copy LinkShare onShare on Share on Share on
    Deven Choksey released a Accumulate report for Aurobindo Pharma Ltd. with a price target of 1320.0 on 31 Jul, 2025.
    logo
    Mankind Pharma Ltd.
    30 Jul 2025, 04:13PM
    2567.20
    -0.32%
    Mankind Pharma Q1 Results Preview: Revenue Likely To Rise, Net Profit May Decline
    Mankind Pharma Q1 Results Preview: Revenue Likely To Rise, Net Profit May Decline
    NDTV Profit
    As per Bloomberg estimates, Mankind Pharma's consolidated revenue for the first quarter is expected to rise year-on-year to Rs 3,605.53 crore.
    Copy LinkShare onShare on Share on Share on
    Mankind Pharma Ltd. has an average target of 2784.33 from 3 brokers.
    logo
    Wockhardt Ltd.
    29 Jul 2025
    1667.50
    -1.03%
    How Wockhardt's bet on multi-drug resistant infections is paying off
    Business Standard
    In India, Zaynich will be positioned as a third-line treatment, primarily for ICU patients when other antibiotics have failed
    Copy LinkShare onShare on Share on Share on
    Wockhardt Ltd. has gained 29.45% in the last 6 Months
    logo
    AstraZeneca Pharma India Ltd.
    29 Jul 2025
    9186.00
    -1.65%
    AstraZeneca Weighs Direct-To-Patient Drug Sales In US
    AstraZeneca Weighs Direct-To-Patient Drug Sales In US
    NDTV Profit
    Earlier this month, fellow European drugmaker Roche Holding AG said it was looking into direct sales to bypass players like pharmacy benefit managers.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 164 to 181 in Jun 2025 qtr.
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd